Kymab: Hong Kong's ORI hits first close on Fund II, exits Kymab

Hong Kong healthcare-focused VC firm ORI Capital has reached a first close of $112 million on its second fund and exited its largest investment, UK biotech developer Kymab, as part of a $1.1 billion deal.